PAREA at THE REAL Summit NYC: access, adoption and the future of psychedelic care

How can innovation in mental health translate into care that people can access and afford? This was among the questions discussed at THE REAL Mental Health Foundation Summit in New York on 22–23 October 2026, which brought together investors, founders, clinicians, policymakers and patient advocates at AllianceBernstein’s Hudson Yards headquarters.

Representing PAREA, Tadeusz Hawrot moderated the panel “Psychedelic Medicine in 2026: Access, Adoption & Scale,” exploring how access to psychedelic treatments could be broadened while keeping care safe.

Tadeusz was joined by Rachel Self, Director of Patient Advocacy and Stakeholder Management at Otsuka; Glen Coppersmith, Director of the Proactive Health Office at ARPA-H, within the US Department of Health and Human Services; and Judy Blumstock, Founder and CEO of Diamond Therapeutics.

Making access work for patients

The discussion covered different treatment models, patient support, affordability and the questions that public research can help answer. Bringing together perspectives from patient advocacy, government research and biotechnology allowed participants to consider how development and delivery decisions could affect the people these treatments are intended to serve.

These issues are closely connected to PAREA’s work in Europe. Regulatory approval is an important milestone, but patients’ ability to receive treatment also depends on reimbursement, trained professionals, suitable facilities and the availability of support before, during and after treatment.

As psychedelic medicines progress through development, decisions about how care is organised will influence both access and patients’ experience of treatment. Affordability and scalability therefore need to be considered alongside the quality and safety of care.

Connecting research, care and investment

The summit offered an opportunity to discuss these questions with people working in different parts of the mental health sector, including those developing treatments, funding research and supporting patients.

For PAREA, exchanges with colleagues in the United States are valuable as Europe develops its own approaches to psychedelic research and access. Different health systems face different constraints, but there is scope to learn from one another about treatment delivery, evidence generation and the barriers patients encounter.

Tadeusz welcomed the conversations both during the panel and throughout the summit. Understanding how researchers, patient advocates, public institutions and investors approach these questions helps inform PAREA’s engagement with European policymakers and healthcare stakeholders.

Thank you to fellow panellists Rachel Self, Glen Coppersmith and Judy Blumstock, and to Shawn Lesser, Heather Kelly and THE REAL Mental Health Foundation team for organising the summit.

Next
Next

PAREA in Cork: mental health across policies and the role of psychological care